In vivo, cardiac-specific knockdown of target protein, Malic Enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA
journal contribution
posted on 2014-01-09, 00:00 authored by J. Michael O’Donnell, Asha Kalichira, Jian Bi, E. Douglas LewandowskiThis study examines the feasibility of using the adenoviral delivery of DNA for a non-native microRNA to suppress
expression of a target protein (cytosolic NADP+-dependent malic-enzyme 1, ME1) in whole heart in vivo, via an
isolated-heart coronary perfusion approach. Complementary DNA constructs for ME1 microRNA were inserted into
adenoviral vectors. Viral gene transfer to neonatal rat cardiomyocytes yielded 65% suppression of ME1 protein.
This viral package was delivered to rat hearts in vivo (Adv.miR_ME1, 1013 vp/ml PBS) via coronary perfusion,
using a cardiac-specific isolation technique. ME1 mRNA was reduced by 73% at 2-6 days post-surgery in heart
receiving the Adv.miR_ME1. Importantly, ME1 protein was reduced by 66% (p<0.0002) at 5-6 days relative to
sham-operated control hearts. Non-target protein expression for GAPDH, calsequestrin, and mitochondrial malic
enzyme, ME3, were all unchanged. The non-target isoform, ME2, was unchanged at 2-5 days and reduced at day 6.
This new approach demonstrates for the first time significant and acute silencing of target RNA translation and
protein content in whole heart, in vivo, via non-native microRNA expression.
Funding
NIH grants: R37 HL49244 (Lewandowski MERIT), R01 HL62702.
History
Publisher Statement
This is a copy of an article published in the Current Gene Therapy © 2012 Bentham Science Publishers. The final publication is available at http://www.benthamscience.com/cgt/index.htmPublisher
Bentham Science PublishersLanguage
- en_US